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TNF-alpha blockers in inflammatory bowel diseases: practical
consensus recommendations and a user's guide
Abstract
More than seventy years after their initial characterisation, the aetiology of inflammatory bowel diseases
remains elusive. A recent review evaluating the incidence trends of the last 25 years concluded that an
increasing incidence has been observed almost worldwide. A north-south gradient is still found in
Europe. Genetic associations are variably reproduced worldwide and indicate a strong impact of
environmental factors. Tumour necrosis factor alpha (TNF-alpha) has been shown to play a critical role
in the pathogenesis of inflammatory bowel disease (IBD). TNF-alpha blockers are biological agents that
specifically target this key cytokine in the inflammatory process and have become a mainstay in the
therapy of inflammatory bowel diseases. This paper reviews the necessary investigations before using
such agents, the use of such agents in pregnancy and lactation, the role of co-immunosuppression, how
to monitor efficacy and safety, dose-adaptation, and the decision as to when to switch to another
TNF-alpha blocker. Finally it gives recommendations for special situations. Currently there are three
TNF-alpha blockers available for clinical use in IBD in Switzerland: infliximab (Remicade),
adalimumab (Humira) and certolizumab pegol (Cimzia). Infliximab is a chimeric monoclonal antibody
composed of a human IgG1 constant region and a murine variable region and is administered
intravenously. Adalimumab is a humanised monoclonal antibody, with both human IgG1 constant and
variable regions. Certolizumab pegol is a pegylated, humanised monoclonal anti-TNF fragment antigen
binding fragment. Both adalimumab and certolizumab pegol are administered by subcutaneous
injection. The efficacy and safety of TNF-alpha blockers in Crohn's disease has been reviewed. The
authors conclude that the three above-mentioned agents are effective in luminal Crohn's disease. In
fistulizing Crohn's disease, TNF-alpha blockers other than infliximab require additional investigation.
Current opinion SWiSS MED WkLy 20 09 ; 139 ( 19–20 ) : 278–287 · www.smw.ch
Peer reviewed article
2
TNF-α blockers in inﬂammatory bowel
diseases: Practical consensus
recommendations and a user’s guide
Isabelle Pache
a
, Gerhard Rogler
b
, Christian Felley
a 1
a
Department of Gastroenterology & Hepatology, University of Lausanne, Switzerland
b
Department of Gastroenterology & Hepatology, University of Zurich, Switzerland
More than seventy years after their initial
characterisation, the aetiology of inﬂammatory
bowel diseases remains elusive. A recent review
evaluating the incidence trends of the last 25
years concluded that an increasing incidence has
been observed almost worldwide [1]. A north-
south gradient is still found in Europe. Genetic
associations are variably reproduced worldwide
and indicate a strong impact of environmental
factors.
Tumour necrosis factor α (TNF-α) has been
shown to play a critical role in the pathogenesis of
inﬂammatory bowel disease (IBD).TNF-α block-
ers are biological agents that speciﬁcally target
this key cytokine in the inﬂammatory process and
have become a mainstay in the therapy of inﬂam-
matory bowel diseases. This paper reviews the
necessary investigations before using such agents,
the use of such agents in pregnancy and lactation,
the role of co-immunosuppression, how to moni-
tor efﬁcacy and safety, dose-adaptation, and the
decision as to when to switch to another TNF-α
blocker. Finally it gives recommendations for spe-
cial situations.
Currently there are three TNF-α blockers
available for clinical use in IBD (table 1) in
Switzerland: inﬂiximab (Remicade
®
), adalimumab
(Humira
®
) and certolizumab pegol (Cimzia
®
) [2].
Inﬂiximab is a chimeric monoclonal antibody
composed of a human IgG1 constant region and a
murine variable region and is administered intra-
venously. Adalimumab is a humanised mono-
clonal antibody, with both human IgG1 constant
and variable regions. Certolizumab pegol is a pe-
gylated, humanised monoclonal anti-TNF frag-
ment antigen binding fragment. Both adali-
mumab and certolizumab pegol are administered
by subcutaneous injection.
The efﬁcacy and safety of TNF-α blockers in
Crohn’s disease has been reviewed [3]. The au-
thors conclude that the three above-mentioned
agents are effective in luminal Crohn’s disease. In
ﬁstulizing Crohn’s disease, TNF-α blockers other
than inﬂiximab require additional investigation.
Key words: Crohn’s disease; ulcerative colitis; in-
ﬂiximab; adalimumab; certolizumab pegol
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Abbreviations
TNF-α Tumour necrosis factor a
IBD inﬂammatory bowel disease
BW body weight
PEG polyethylene glycol
NYHA New York Heart Association
HBV Hepatitis B virus
HBsAg Hepatitis B surface antigen
MRI Magnetic resonance imaging
CMV cytomegalovirus
TB tuberculosis
INH isoniazide
HIV human immunodeﬁciency virus
anti-HBc Ab anti-hepatitis B core antibody
ISS immunosuppressive
HAV Hepatitis A virus
HPV human papilloma virus
CD Crohn’s disease
CDAI Crohn’s disease activity index
CRP C-reactive protein
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Medical history (see table 2)
A thorough medical history must be taken be-
fore the introduction of a TNF-α blocker as any
existing chronic non IBD disease could be exacer-
bated. NYHA III and IV cardiac failure is a con-
traindication for TNF-α blocker therapy [4, 5].
Any history of neurological problems must in par-
ticular be looked for as case reports of demyeli-
nating neuropathies secondary to the use of a
TNF-α blocker have been described in several re-
ports [6]. TNF-α blockers may also be associated
with lymphomas and other malignancies, and
they should thus be used with caution in patients
with a history of neoplasia.
TNF-α blockers are also only indicated when
no stricture is suspected as a cause of symptoms.
TNF-α blockers can induce elevation of liver
enzymes and reactivate chronic viral hepatitis,
with chronic hepatitis B being a major concern
since severe ﬂare-ups have been described []. In
case of doubt, specialist advice should be sought
before initiation of TNF-α blocker therapy.
A detailed history of any heart failure, chronic
liver disease, neurological disorder and neoplasia
is mandatory
Anti-TNF-α agents are contra-indicated in
NYHA III or IV cardiac insufﬁciency and must be
used with caution in patients with chronic liver
disease, neurological pathology or history of ma-
lignancy, especially lymphoma.
Screening for infections, blood tests,
urine and stool analysis
Active infections may be exacerbated and qui-
escent infections activated during TNF-α blocker
therapy [] and patients should therefore be
screened for infections before starting treatment.
Screening tests can be applied either to all pa-
tients or be individualised according to their med-
ical history.
If a patient has a suspected abscess, an MRI is
indicated [9]. In presence of a relapse of colitis, a
superinfection with Clostridium difﬁcile or CMV
must be ruled out. Patients with a history of re-
current urinary tract infections should have a
urine culture [10].
Potential reactivation of granulomatous dis-
eases, in which host defences are predominantly
macrophage-dependent, is of particular concern.
Active or latent tuberculosis should be excluded.
A tuberculin skin test (Mantoux test) can give
false results in patients with IBD as it is negatively
affected by immunosuppressant therapy and
falsely positive following BCG vaccination [11].
Apart from taking a clinical history, both an in
Active substance Mode of use Properties and action Registered
(trade name) Recommended dosage in IBD mechanism indications
(for adults)
Inﬂiximab Intravenous infusion Chimeric monoclonal antibody Crohn’s disease in adults
(Remicade
®
) 5 mg/kg BW in weeks 0, 2, and 6, to TNF-α and children (from 6 years)
then every  weeks (maintenance therapy) Ulcerative colitis
or 5 mg/kg on reappearance of the Rheumatoid arthritis
symptoms (repeat treatment) Psoriatic arthritis
Ankylosing spondylitis
Plaque psoriasis
Adalimumab Subcutaneous injection Human monoclonal antibody Crohn’s disease in adults
(Humira
®
) 160 mg in week 0, 0 mg in week 2, to TNF-α Rheumatoid arthritis
and then 40 mg every 2 weeks Psoriatic arthritis
Plaque psoriasis
Ankylosing spondylitis
Certolizumab pegol Subcutaneous injection PEG*-conjugated Fab fragment Crohn’s disease in adults
(Cimzia
®
) 400 mg in weeks 0, 2, and 4, then of a recombinant, humanised
every 4 weeks antibody to TNF-α
As at: December 200
Table 1
Overview of the
TNF-α antagonists
registered for the
treatment of Crohn’s
disease in Switzer-
land.
Investigations before the use of TNF-
α
blockers
Evaluation If yes
1. Suspicion of abscess conﬁrmed on MRI Contra-indicated
2. Flare of colitis
a. Clostridium difﬁcile toxin positive in stools Contra-indicated
b. CMV infection proven by biopsies Contra-indicated
3. Cardiac failure NYHA III or IV Contra-indicated
4. Neurological disease Use with caution
5. Chronic liver disease Use with caution
6. History of malignancy Use with caution
. Positive interferon-gamma assay for tuberculosis and/or chest Contra-indicated
X-ray prior to a 4 week-treatment with isoniazid
. Positive HIV uncontrolled disease Contra-indicated
9. Positive HBV serology
a. elevated liver enzymes Start treatment
b. normal liver enzymes Discuss prophylaxis
c. isolated anti-HBc Ab Monitoring and booster
10. Negative Varicella zoster virus history and serology Discuss vaccine
11. Recurrent urinary tract infections Urine analysis
12. Patient has travelled to or lived in a tropical area Parasites in stools
13. Abnormal complete blood cell count or CRP Further evaluations
14. Abnormal transaminases levels Further evaluations
15.Women: gynaecological examination >1 year Obtain exam
Table 2
indications and contra-indications of antiTNF-α therapy with respect to findings during
screening before treatment.
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vitro test (T-cell Interferon-γ Releasing Assay-
TIGRA-) and a chest X-ray should be performed,
since latent TB infections can affect the abdomi-
nal and mesenteric area, with the result that a
chest X-ray on its own is often not sufﬁcient.
TIGRAs are minimally (Quantiferon-TB
®
Gold)
or unaffected (T-SPOT.TB
®
) by immunosuppres-
sant therapy. A Swiss conference has recom-
mended that both an interferon gamma assay for
tuberculosis and a chest X-ray be undertaken [12].
Patients with a positive screening should ﬁrst be
treated for at least 4 weeks with isoniazid before
starting TNF-α blocker therapy. After a month of
INH treatment for latent TB, anti-TNF-α ther-
apy can be initiated as recommended for all pa-
tients.
Moreover endemic mycoses can lead to fatal
invasive fungal infections in patients treated with
TNF-α antagonists [13].
Results from two studies indicate that anti-
TNF-α therapy with inﬂiximab [14] or etaner-
cept [15] may be associated with increased mor-
tality in patients with liver failure due to alcoholic
steatohepatitis. Treatment should not be insti-
gated in such patients.
Viral diseases may take a life-threatening
course in a patient taking a TNF-α blocker. Case
reports of reactivation of chronic hepatitis B have
been described. No acute ﬂare-up of hepatitis has
been reported in the literature in concomitant
chronic hepatitis C []. A blood test to rule out an
HBV infection should thus be performed. Pa-
tients with a positive HBsAg and elevated liver
enzymes must receive a speciﬁc treatment. In pa-
tients with positive HBsAg and normal liver en-
zymes, a prophylaxis must be discussed and regu-
lar monitoring of liver enzymes and HBV-DNA
be performed. Patients with a negative serology
should be vaccinated. Uncontrolled HIV infec-
tion is a contra-indication to TNF-α blocker
therapy. Due to enhancement of abnormal Pa-
panicolaou smears and cervical dysplasia, proba-
bly in relation with chronic human papilloma
virus infection in women taking immunosuppres-
sants for IBD, a gynaecological examination is
mandatory before starting TNF-α blocker ther-
apy [16, 1] (table 2).
Before treatment with TNF-α antagonists is
initiated, all patients should be checked both for
an active and for an inactive (latent) TB infection.
This check should include the following steps:
– Detailed medical history
– In-vitro test: Quantiferon-TB
®
Gold or T-
SPOT.TB
®
Vaccination Dose(s) Schedule
Maintenance of routine vaccinations
Diphteria-tetanus vaccine 1 Maintenance: every 10 years (1 dose)
± pertussis Combined vaccine available
± inactivated poliomyelitis
Inﬂuenza vaccine 1 Revaccination annually (1 dose)
23-valent pneumococcal vaccine 1 Maintenance: every 5 years (1 dose)
Vaccinations to be discussed before initiating an anti-TNF-
α
therapy
Hepatitis B vaccine 3 0, 1 and 6 months Additional dose(s) if anti-HBs Ab <100
Varicella vaccine 2 0 and 1 months In patients with negative serology and
temporarily off ISS
Tick borne-encephalitis vaccine 3 0, 1 and 6 months Maintenance every 10 years if continuing
residence in endemic area (1 dose)
Human papilloma virus vaccine 3 0, 2 and 6 months Recommended for women <25 year-old with
normal Pap smear
Vaccinations for travellers (depending on risk of exposure)
Hepatitis A vaccine 2 0 and 6 months Combined HAV-HBV vaccine available
Typhoid (non oral) vaccine 1
Poliomyelitis (non oral) vaccine 1
Japanese encephalitis vaccine 1
4-valent ACWY meningococcal vac. 1
Rabies vaccine 3 0, 1 and 4 weeks
Live vaccines contra-indicated in patients on ISS
Combined measles-mumps-rubella
Varicella
Oral poliomyelitis
Oral typhoid
Yellow fever
Sources: Bundesamt für Gesundheit (BAG) [Swiss Federal Ofﬁce of Public Health] Richtlinien und Empfehlungen
[Guidelines and Recommendations]: Impfungen für Auslandsreisende [Vaccinations for those travelling abroad], version: January 200;
BAG Richtlinien und Empfehlungen [Swiss Federal Ofﬁce of Public Health Guidelines and Recommendations]: Schweizerischer Impf-
plan 200 [Swiss Vaccination Plan 200], version: January 200; drug compendia of the relevant vaccines
Table 3
Recommendations
for vaccinations.
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– Chest X-ray
The following tests must also be carried out:
– HBsAg, anti-HBcAb
– HIV serology
– complete blood cell count
– transaminases
Vaccinations
The recommendations are summarised in
table 3.
Vaccines are under used in adult patients with
IBD [1] even though it is known that these pa-
tients are at higher risk of severe infections. Sev-
eral studies have shown that patients with a
chronic immunological illness treated with im-
munosuppressants have an adequate antibody re-
sponse to vaccine administration and do not expe-
rience increased clinical activity of the underlying
chronic disease as a result of the immune re-
sponse to immunisation [19–21]. Vaccinations
should, however, preferentially be given prior to
immunosuppressive (ISS) therapy or in patients
with an ISS monotherapy in order to minimise
the risk of decreased response. Live vaccines (oral
poliomyelitis, oral typhoid, yellow fever and
combined measles-mumps-rubella vaccines, see
table 3) are contra-indicated in patients taking
immunosuppressants, but may be given at least 3
weeks before initiation and ≥3 months after cessa-
tion of immunosuppressive therapy or at any time
in patients on steroids monotherapy at a daily
dose <20 mg [].There is currently no data on use
of live vaccines in patients on single TNF-α
blocker therapy and they are thus contra-indi-
cated on safety grounds.
Regular immunisations in adults include
booster doses against diphtheria and tetanus (dT)
and, in persons aged 65 or over, vaccination
against inﬂuenza and pneumococci. Any addi-
tional immunisations with inactivated vaccines
recommended in speciﬁc indications or for at-risk
groups should be carried out after consideration
of the patient’s individual risk and at the doctor’s
discretion.
Vaccinations against inﬂuenza and pneumo-
cocci are recommended for at-risk patients of any
age and for persons aged 65 years or over.The in-
ﬂuenza vaccine must be given annually and the
23-valent pneumococcal vaccine every 5 years in
case of continuous immunosuppressive therapy.
In women, human papilloma virus (HPV) vacci-
nation should be considered owing to the risk of
cervical cancer caused by HPV. Any young
woman who is not yet sexually active should be
vaccinated before anti-TNF-α therapy is started.
In the case of women who have not been vacci-
nated against HPV as an adolescent, a cervical
smear with cytodiagnosis (PAP test) should be
carried out each year on account of the risk of
HPV infection.
Children must receive the usual scheduled
vaccinations and adults the maintenance routine
vaccinations against tetanus and diphtheria every
10 years. Some countries propose administering a
combined vaccine for diphtheria, tetanus, pertus-
sis and inactivated poliomyelitis due to the in-
creased prevalence of pertussis and frequent in-
ﬂux of tourists.
In naïve patients, a three-dose vaccination
against hepatitis B is recommended with evalua-
tion of response (anti-HBs-Ab titer) 1 month
after the ﬁnal injection. Additional vaccine dose(s)
may be necessary to obtain an adequate response.
A combined HAV-HBV vaccine may be consid-
ered [, ]. As a severe form of varicella has been
described in IBD patients on TNF-α blockers,
two doses of varicella zoster vaccine can be con-
sidered for patients with a negative history and
serology for varicella zoster virus [22]. This is a
live attenuated virus vaccine and can thus only be
given to patients not under ISS therapy. A tick
born-encephalitis vaccine should be proposed
every 10 years for patients living in endemic areas
[].
– Vaccinations with live vaccines (see table 3)
are contraindicated during treatment with bi-
ological agents as with other immunosup-
pressant therapies. Vaccination with inacti-
vated (killed) vaccines can be carried out dur-
ing anti-TNF-α therapy.
– Usual scheduled and routine maintenance
vaccinations must be given both in paediatric
and adult IBD patients.
– Live vaccines are contra-indicated in patients
on ISS therapy, except if they are on steroid
monotherapy of <20 mg/day.
– Inﬂuenza vaccine should be given annually
and 23-valent pneumococcal vaccine every 5
years.
– Hepatitis B vaccination should be adminis-
tered in naive patients. Other vaccinations
(Hepatitis A, varicella, human papilloma virus
and tick borne-encephalitis) should be pro-
posed to speciﬁc patients.
Pregnancy, lactation and contraception
Pregnancy
Inﬂiximab is classiﬁed by the Food and Drug
Administration (FDA) as a pregnancy class B
agent meaning that there has as yet been no docu-
mented human toxicity. However, data are limited
and come mostly from uncontrolled studies.
Mahadevan et al. were the ﬁrst to report the in-
tentional use of inﬂiximab during pregnancy [23].
Ten women were identiﬁed of whom eight re-
ceived inﬂiximab throughout their pregnancy. All
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ten pregnancies ended in a live birth. None of the
infants had any congenital malformation or in-
trauterine growth retardation. None were small
considering their gestational age parameters.
Three infants were premature and one had low-
birth weight. More recently, Schnitzler et al. re-
ported about 20 pregnancies in which inﬂiximab
was needed to maintain remission and intention-
ally continued in the ﬁrst 2 trimesters [24]. Inﬂi-
ximab was stopped thereafter, given the demon-
strated risk of increased maternofoetal transfer of
inﬂiximab during the last trimester. No congeni-
tal abnormalities were observed in the children.
Inﬂiximab was restarted in 14 women immedi-
ately after delivery.
Data are also available from a safety registry.
Centocor maintains a safety database for all re-
ports of pregnancy. Katz et al. analysed 146 cases
with inﬂiximab exposure before pregnancy or
after pregnancy was conﬁrmed [25]. Inﬂximab ex-
posure during pregnancy resulted in outcomes
that did not differ from those in the general US
population of pregnant women and pregnant
women with Crohn’s disease not exposed to in-
ﬂiximab. Finally, Vasiliaukas et al measured inﬂix-
imab levels in the newborn of a mother treated
with inﬂiximab [26]. Six weeks after delivery, the
breast-fed infant’s serum inﬂiximab level was 39.5
ug/mL which is a clinically signiﬁcant level. In-
ﬂiximab was not detected in the breast milk. Se-
rial measurements revealed a continued slow de-
cline in the infant’s inﬂiximab levels during the
following 6 months, despite resumption of breast-
feeding.
Adalimumab is also classiﬁed by the Food and
Drug Administration (FDA) as a pregnancy class
B agent. However only case reports have been
published on its use in Crohn’s disease during
pregnancy.
There are no published data regarding cer-
tolizumab pegol use in pregnancy.
It should also be kept in mind that there can
be an exacerbation of Crohn’s disease during
pregnancy.
– Women of child-bearing age should be in-
structed to avoid becoming pregnant during
anti-TNF-α therapy by using appropriate
methods of contraception. The doctor should
weigh the risks and beneﬁts of such therapies
during pregnancy and consult expert centres
for advice in such cases.
– If, however, administration is necessary to
control IBD, the beneﬁts of inﬂiximab seem
to outweigh the risks when given during the
ﬁrst two trimesters of pregnancy. Adalimubab
is also probably safe during pregnancy.
– Until further evidence is available, inﬂiximab
should be stopped during the last trimester of
pregnancy.
Anti-TNF-α can be safely restarted after delivery.
How should anti-TNF-
α
therapy be started? Co-immunosuppression
with TNF-
α
blockers?
The best time to introduce anti-TNF-α ther-
apy remains controversial and only limited data
are available [2]. In Switzerland, TNF-α block-
ers are reimbursed only when conventional ther-
apy such as steroids and/or immunosuppressants
has failed. Thus, early aggressive therapy with
TNF-α blockers is not recommended in our
country.We still feel that, due to the limited long-
term safety data, TNF-α blockers should be re-
served for patients failing conventional immuno-
suppression.
When initiating anti-TNF-α therapy, one
needs to decide whether existing treatment with
steroids or immunomodulators such as 6-mercap-
topurine (6-MP), azathioprine (AZA), or
methotrexate (MTX) should be continued and
combined with the TNF-α blocker or whether it
should be stopped. The use of TNF-α blockers is
associated with the formation of antibodies
against these substances, thus decreasing their ef-
ﬁcacy. Baert et al. showed that antibodies against
inﬂiximab were detected in 61% of the patients
treated episodically with inﬂiximab [2]. The de-
velopment of these antibodies was associated with
an increased risk of infusion reactions and a re-
duced response to treatment. Concomitant im-
munosuppressive therapy with azathioprine, 6-
mercaptopurine or methotrexate reduced the im-
munogenic response. This observation led to the
concept of co-immunosuppression duringTNF-α
blocker therapy. However, a scheduled mainte-
nance therapy after an induction therapy instead
of an episodic treatment is associated with much
less immunogenicity, which led to the high levels
of anti-inﬂiximab antibodies reported by Baert et
al. [2–30].
Recently, rare but fatal, cases of hepatosplenic
T cell lymphoma have occurred in young patients
co-treated with TNF-α blockers and azathio-
prine, which suggests that co-immunosuppression
may be hazardous, especially in young males [31].
In addition, one trial looked speciﬁcally at the
withdrawal of immunosuppression in patients
with Crohn’s disease treated with scheduled main-
tenance therapy [32]. The conclusion was that
continuation of immmunosuppressors for more
than 6 months offers no clear beneﬁt over sched-
uled inﬂiximab monotherapy. The only caveat is
that CRP levels were signiﬁcantly higher and in-
ﬂiximab trough levels signiﬁcantly lower in the
discontinuation group.The impact of these obser-
vations on the long-term outcome is still unclear
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but needs further evaluation, since in Crohn’s dis-
ease patients treated with scheduled maintenance
infusions of inﬂiximab, the trough serum concen-
tration of inﬂiximab predicts clinical outcome
[33]. The signiﬁcance of the serum trough level
has also been shown for adalimumab [34]. In this
study, trough levels signiﬁcantly correlated with
clinical response (6.93 for complete versus 5.52
for partial, versus 3.51 for non-responders, p =
0.009). Another study could not ﬁnd any link be-
tween adalimumab trough levels and clinical re-
sponse [35]. No data currently exist concerning
the trough levels for certolizumab pegol.
The SONIC study, presented at UEGW
200 in Vienna, speciﬁcally investigated the role
of a concomitant immunomodulator with inﬂi-
ximab in azathioprine naïve patients suffering
from Crohn’s disease. Patients were randomised
to receive azathioprine 2.5 mg/kg + placebo, in-
ﬂiximab 5 mg/kg + placebo or both inﬂiximab and
azathioprine. The primary end-point of the study
was the steroid-free remission at week 26. 5% of
the patients on both drugs were in clinical remis-
sion without corticosteroids at week 26 versus
44% in the inﬂiximab alone group and 31% in the
azathioprine alone group. This indicates that
about 10% of all patients beneﬁt from the combi-
nation of both drugs.We feel that the beneﬁt-risk
ratio should be carefully evaluated when consid-
ering the combination of both drugs. Further-
more the conﬁrmation of this beneﬁt after one
year of therapy has not yet been proven. Finally as
already mentioned the continuation of immuno-
suppressants beyond 6 months seems to offer no
clear beneﬁt over scheduled inﬂiximab monother-
apy.
In contrast another study by Feagan and col-
leagues demonstrated no additional effect of a
combination of inﬂiximab with methotrexate in
patients with active CD (also treated with
steroids) [36].
Azathioprine and 6 MP
– For patients naïve to azathioprine or 6-mer-
captopurine, a monotherapy with TNF-α
blockers is recommended; some patients may
however, also beneﬁt from combination ther-
apy.
– For patients already treated with a TNF-α
blocker and azathioprine or 6-mercaptop-
urine and in remission (and with normal CRP
levels), we generally recommend ceasing aza-
thioprine or 6-mercaptopurine therapy and
pursuing monotherapy with the TNF-α
blocker.
– Patients not completely in remission with a
combined therapy of a TNF-α blocker and
azathioprine or 6-mercaptopurine should be
discussed with a reference centre.
– An episodic therapy with TNF-α blockers
should be avoided
Glucocorticoids
The aim of anti-TNF-α therapy is to reduce
steroid ingestion and, if possible, these should be
gradually withdrawn entirely. Regular observa-
tion is necessary as long as the patient has not
achieved remission.
Methotrexate
The combination of methotrexate and inﬂix-
imab is not more effective than inﬂiximab alone
in active CD patients. Therefore, the combina-
tion of TNF-α blockers and methotrexate should
be avoided.
Efﬁcacy and safety monitoring
Monitoring
The long-term outcome of treatment with in-
ﬂiximab in 614 patients with Crohn’s disease has
recently been published [3]. Sustained beneﬁt
was observed in 63% of patients receiving long-
term treatment. The need for hospitalisation, sur-
gery and steroids was decreased especially in the
scheduled treatment group.
Patients should be followed up at each injec-
tion during the induction phase and then every
eight weeks during the maintenance therapy with
a TNF-α blocker, not only to allow the physician
to evaluate the efﬁcacy and tolerability of the
therapy, but also to support patient adherence. In
addition to the general monitoring during inﬂam-
matory bowel disease, regular checks on the major
laboratory parameters are recommended at each
patient visit.
The activity of TNF-α against tumours in
laboratory models of carcinogensis and poten-
tially in humans raises the possibility that TNF-α
blockers might increase the risk of malignancy.
Up to now, data on the risks of solid malignancy
and lymphomas are conﬂicting. Long term follow
up studies are still needed, however no increased
risk for malignancies was observed in the TREAT
registry with nearly 15,000 patient-years of fol-
low-up [3]. Another study evaluated the long-
term safety of inﬂiximab in patients with IBD
treated over a 14-year period and concluded that
inﬂiximab has a good overall safety proﬁle [39].
In the largest studies evaluating the efﬁcacy
and the safety of adalimumab, certolizumab pegol
and inﬂiximab, response was determined as a de-
crease in CDAI of ≥0 or ≥100 points 6 to 10
weeks after the ﬁrst induction dose. Clinical and
biological evaluation was performed every other
week during the ﬁrst two months in most studies
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then every 4 to  weeks during the maintenance
therapy [5].
Time point for exclusion of non-responders
The Crohn’s Disease Activity Index (CDAI)
has been used to judge efﬁcacy in clinical trials. A
study reviewed the optimal response criteria for
the CDAI for induction studies in patients with
mildly to moderately active Crohn’s disease [40].
They conclude that the efﬁciency criteria can be
improved by using either a decrease in CDAI ≥0
points for the last two consecutive visits, or a de-
crease in baseline CDAI ≥100 points.
Non-response is deﬁned as a decrease in
CDAI of less than 100 points from baseline after a
full induction, on an average 6 to 10 weeks after
the ﬁrst injection.
Frequency of efﬁcacy and safety evaluation
On the basis of study designs and in view of
the importance of monitoring during the initial
phase of treatment with TNF-α blockers, it is
recommended that patients be seen every other
week during the induction phase (week 0, 2, and
4). Patients should be monitored every two
months thereafter for as long as the anti-TNF-α
therapy continues, to check efﬁcacy, safety, and
adherence.
Method for evaluation of efﬁcacy
Efﬁcacy of a TNF-α blocker therapy is based
on clinical signs and symptoms as well as biologi-
cal parameters (table 4). The aim of treatment is
to achieve steroid-free remission. Clinical symp-
toms evaluated should include frequency of bowel
movements per 24 hours, level of pain, general
status, possible extra-intestinal symptoms, fever
and steroid use. Blood examinations must at least
include a full blood count and a marker of inﬂam-
mation (CRP, ferritin). Until now, only a change
in the faecal calprotectin value has been shown to
be signiﬁcant but there is not enough evidence to
suggest that it can replace CRP and/or ferritin as
a measure of inﬂammation. Endoscopy is pro-
posed to evaluate mucosal healing, CT scan or
MRI to conﬁrm ﬁstula closure (table 4).
The aim of TNF-α blocker therapy is to
achieve a steroid-free remission. Complete blood
count, CRP, and liver function parameters should
be checked at every appointment, i.e. every two
months, in all patients being treated with TNF-α
antagonists.
Method for evaluation of safety
A recent case control study showed that the
odds ratio for opportunistic infections was in-
creased at 4.4 with inﬂiximab use and at 12.9 when
≥2 immunosuppressors were used [41]. The risk of
sepsis, malignancies and myelosuppression is much
greater if biologicals are administered in combina-
tion with another immunosuppressive agent [5].
Patients must be instructed concerning possible
adverse effects in order to be able to recognise
early symptoms and should have rapid 24/24-hour
phone access to a clinical team. In febrile patients,
especially those with neutropenia or lymphopenia,
a thorough clinical examination is mandatory and
additional tests may be required [].
Regular monitoring is necessary. Abnormal
full blood count, renal or liver dysfunction should
be ruled out through blood tests. Vaccinations
must be kept up to date. In women, a regular gy-
naecological examination is mandatory to exclude
lesions due to a chronic human papilloma virus
infection [, 16, 1].
– Regular biological examinations are necessary.
– Patients should be informed about possible
adverse effects.
– Vaccinations should be updated.
– Women should have a regular gynaecological
examination.
Preventive attitude in case of travel
or holidays
As for every traveller, vaccinations are indi-
cated when staying in high risk areas. Live vac-
cines (yellow fever, oral typhoid, oral po-
liomyelitis, combined measles-mumps-rubella
vaccines) are contra-indicated in patients taking
TNF-α blockers [16]. Patients going to endemic
areas should receive either a prophylactic or an
early therapeutic treatment against malaria [42].
Patients should carry with them a phone number
enabling them to contact a clinical team in case of
emergency at any time [, 1]. Antibiotics such as
ciproﬂoxacine and/or metronidazole may be pro-
vided for use in case of suspected superinfected
colitis during the holiday period.
– Except for live vaccines, vaccinations and
chemoprophylaxis against malaria are identi-
cal to those usually recommended.
– Patients should have a rapid 24/24-hour
phone number contact in case of emergency.
– Antibiotics may be given to be taken if symp-
toms develop.
Mandatory Clinical examination:
Number of bowel movements per day
Level of abdominal pain
Extra-intestinal symptoms
Fever
Other medications
Laboratory:
CRP
Complete blood count
Transaminases
Recommended Imaging to be discussed according
to clinical symptoms:
Endoscopy
CT scan or MRI
Check on vaccination status
PAP test
Table 4
Recommendations
for general iBD
monitoring.
25SWiSS MED WkLy 20 09 ; 139 ( 19–20 ) : 278–287 · www.smw.ch
Additional safety aspects in case of home
therapy
Whilst inﬂiximab is administered by intra-
venous infusion, adalimumab or certolizumab
pegol can be administered by subcutaneous injec-
tion. All 3 medications can be provided at home
or at a medical practice. Adequate instruction is
essential for patients who wish to self administer
the TNF-α blocker. The duration of the induc-
tion phase corresponds roughly to the time taken
by the patient to learn the injection technique and
the possible complications. Whatever the case,
patients should be monitored regularly.
– Patients with home therapy should have the
same frequency of monitoring as patients
with an hospital-based therapy.
– Patient education about possible adverse ef-
fects and risk of misuse of a TNF-α blocker is
crucial.
– A minimal documentation should be commu-
nicated to the prescribing physician on a reg-
ular basis (e.g. administration) (table 5).
– Self-injection or administration at home can
be considered if the patient is in stable remis-
sion, although no sooner than the end of the
induction phase.
Dose increase and switch to another TNF-
α
blocker
Dose-increase
The ACCENT I study has shown that 30% of
patients on the 5 mg/kg scheduled treatment had
to increase the dose to 10 mg/kg, approximately
90% of whom re-established response, and 26%
of patients on the 10 mg/kg scheduled treatment
had to increase the dose to 15 mg/kg [43], approx-
imately 0% of whom achieved a response. It has
been shown that dose intensiﬁcation can be
achieved with an increase in dose, a decrease in in-
terval or both. Using this deﬁnition, Regueiro et
al. demonstrated that, 30 months after beginning
inﬂiximab, 54% of the patients had a change in
their initial dose and/or interval of inﬂiximab ad-
ministration [44]. Seventy six percent of these pa-
tients regain response with dose intensiﬁcation.
The Leuven group also reported their experience
of analysing long term treatment with inﬂiximab
in 614 consecutive Crohn’s disease patients [45].
They deﬁned an intervention as every shortening
of the interval between infusions, an increase of
the dose of inﬂiximab or a change from episodic
to scheduled treatment every  weeks. Fifty per-
cent of the patients needed such an intervention.
A shortening of the interval became necessary in
10 patients (20%), an increase of the dose in 144
patients (26%) and an increase of the dose plus a
reduction of the interval in 21 patients (4%).
These interventions were successful since only
about one ﬁfth of patients had to stop inﬂiximab
treatment due to loss of response.
The beneﬁts of dosage adjustment have also
been shown for adalimumab in Crohn’s disease
[46]. In the CHARM trial, of the 260 patients ran-
domised to receive adalimumab 40 mg every
other week, 1 (2%) switched to open-label 40
mg every week for ﬂare or non response. After the
dosage adjustment, 45% achieved clinical remis-
sion (CDAI ≤150) and 6% obtained clinical re-
sponse (diminution of at least 0 points in the
CDAI score).
Two studies looked speciﬁcally at the effect of
a re-induction therapy in case of loss of response.
Karmiris et al. assessed the beneﬁt of a 3-week
course of 0 mg of adalimumab weekly as a rescue
therapy for patients who lost response to 40 mg
weekly [35]. Among 25 patients, 15 (60%) exhib-
ited clinical response (12 partial and 3 complete).
Eleven patients were able to sustain clinical re-
sponse thereafter (10 stepping down to 40 mg
every week and one continuing on 0 mg every
week).
Schreiber et al. also evaluated the response to
a re-induction with certolizumab 400 mg at weeks
0, 2 and 4 followed by maintenance therapy (400
mg every 4 weeks) in both relapsers of the active
arm and patients coming from the placebo arm of
the PRECISE 2 study [4]. In the relapsers, the
remission rate was 35% at 6 and 12 months after
re-induction and in patients coming from the
placebo arm 44% after 6 months and 36% after
12 months.
Switch to another TNF-
α blocker
A re-induction of response can also be ob-
tained by switching to another TNF-a blocker. In
the CHARM trial, 50% of the patients had previ-
ously received a TNF-α blocker [4]. The remis-
sion rate was 32% and 31% at week 26 and 52
respectively in the TNF-α blocker experienced
versus 4% and 42% respectively in the TNF-α
blocker naïve patients. In the PRECISE 2 study,
2% of the patients had previously received and
discontinued inﬂiximab [49]. More patients re-
sponded in the inﬂiximab naïve group than in the
inﬂiximab experienced group of patients (69%
versus 44%, p <0.001). Two studies looked speciﬁ-
cally at patients who were intolerant of inﬂiximab
Infections during the previous week
Number of bowel movements per day
Blood in stools (macroscopic)
Arthralgia
Skin disorders
Vital signs
Reason for possible skipped administration
Table 5
Evaluation of efficacy
and safety of home
careTNF-α blockers.
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or had previously responded and then lost re-
sponse. Sandborn et al looked at the efﬁcacy of
adalimumab in this situation [50]. To be included,
patients must have been intolerant of inﬂiximab
or must have had previously responded to inﬂi-
ximab and then lost response. Patients with mod-
erately to severely active Crohn’s disease were
randomised to receive either induction doses of
adalimubab, 160 mg and 0 mg, at weeks 0 and 2,
respectively or placebo at the same time points.
Three hundred and one patients completed the
trial. At week 4, 34 of 159 patients receiving ada-
limubab (21%) achieved clinical remission versus
% in the placebo group. A similar study was
done with certolizumab [51] with 539 patients en-
rolled. At week 6, 62% of the patients achieved
response and 39% remission. Results have also
been presented on the efﬁcacy of a third anti-
TNF-a monoclonal antibody in Crohn’s disease
after failure of two other anti-TNF-α [52]. A clin-
ical response at week 6 was observed in 29 of 50
patients (5%). One centre reported their retro-
spective 3-year experience with adalimumab for
Crohn’s disease with intolerance or lost response
to inﬂiximab [53]. They conclude that half of pa-
tients maintained clinical response at 130 weeks.
Most clinical studies used a washout period
when switching to another TNF-α blocker. The
potential toxicity of a combination of TNF-α
blockers favours this attitude. However patients
who lost response often had low or undetectable
serum levels of TNF-α blockers and high disease
activity.
– An optimal use of each TNF-α blocker is
mandatory.
– In case of loss of response, a dose intensiﬁ-
cation should be attempted either by an in-
crease in dose, a decrease in interval or both.
– In case of no response to a dose intensiﬁca-
tion, the practitioner should seek advice from
a specialist referral centre, to discuss a switch
to another TNF-α blocker.
Recommendations for special cases
Treatment of externally draining ﬁstulas
Once there are no abscesses present and as
soon as all external ﬁstulas have been drained, a
combination of antibiotics with a TNF-α in-
hibitor in a standard induction dosage can be con-
sidered, depending on the patient’s condition.
The anti-TNF-α therapy must be initiated in
accordance with the indication, i.e. using a satura-
tion dose for induction and then a dosage speci-
ﬁed for the relevant substance in the com-
pendium.
There are no data available on treatment with
antibiotics even though these are often used in
practice.
If externally draining ﬁstulas are present, it is
recommended that an imaging technique (pelvic
or abdominal MRI) be used to identify or exclude
abscesses. All abscesses should be eliminated be-
fore anti-TNF-α therapy is started.
Procedure in cases of liver disease
– If transaminases levels (ASAT, ALAT) are ele-
vated up to 3 to 4 times the normal level prior
or during therapy with TNF-α blockers, fur-
ther investigation is necessary to establish the
reason for the abnormal liver function param-
eters. Anti-TNF-α therapy can, however, be
installed or continued. Transaminases levels
should thereafter be checked more frequently,
at monthly intervals, as long as no improve-
ment is observed.
– If the values for ASAT and/or ALAT are more
than 4 times the upper normal value, the anti-
TNF-α therapy should be postponed or dis-
continued. A liver biopsy should be consid-
ered.
Closing remarks
Biotechnologically manufactured TNF-α
blockers are now ﬁrmly established in the treat-
ment regimen of severe active forms of inﬂamma-
tory bowel disease and are an effective treatment
option for patients with IBD who do not respond
adequately to conventional therapy with steroids
or immunomodulators, and, in many patients, en-
able the dose of steroids to be reduced.
With biological agents, as with other drug
therapies, it is imperative to establish the indica-
tion carefully and to take adequate precautionary
measures both before and during treatment. The
purpose of this text, based on the experience of ex-
perts, is to provide gastroenterologists in private
practice with relevant information and practical
recommendations regarding the use of biological
agents. Corresponding consensus recommenda-
tions were also prepared by the European Crohn’s
and Colitis Organisation (ECCO) in 200, and
their publication is expected soon.
This work was supported by an unrestricted grant
from Abbott, Essex Chemie and UCB.
We thank Mrs S. Giddons for editorial assistance.
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